Clinical Trial Update: A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma [Phase 1]

View source ↗

Summary

Phase I feasibility and safety study of fluorescein-specific (FITC-E2) CAR T cells in combination with Folate-Fluorescein (UB-TT170) for osteosarcoma; currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Fluorescein-Specific (FITC-E2) CAR T Cells (FITC-E2 CAR T cells)
• Folate-Fluorescein (UB-TT170) (Folate-Fluorescein (UB-TT170))

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Osteosarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING